Sesen Bio Announces New Appointments to its Board of Directors - Seite 2

In addition to his industry and FDA experience, Dr. Honig has been the PhRMA representative to the International Conference on Harmonisation (ICH) Steering Committee from 2002 to 2021, is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and is currently an associate editor of their flagship journal. Dr. Honig received medical and public health degrees from Columbia University in New York.

“I am honored to join the Sesen Bio Board of Directors,” said Dr. Honig. “Sesen Bio has made tremendous progress in key markets with the upcoming potential product approvals in the US in August and in Europe in 2022 with a promising pipeline to fuel future growth. I look forward to working with the Board and management team in contributing to Sesen Bio’s future success.”

Michael A.S. Jewett, MD, FRCSC, FACS is a prominent Oncologist who is internationally recognized for his life-saving innovations in surgical oncology, his advocacy of patient-centered clinical care, and his contributions to research in the field of bladder cancer. Dr. Jewett is currently a professor in the Departments of Surgical Oncology and Surgery (Urology) at the Princess Margaret Cancer Centre, University Health Network and the University of Toronto. A graduate of Queen’s University, Faculty of Medicine, Kingston, Ontario, Canada, where BCG for bladder cancer was first prescribed, Dr. Jewett completed his Urology training at the University of Toronto, Canada and Memorial Sloane-Kettering Cancer Center in New York. Dr. Jewett has played a leading role in national and international consensus statements, including as a committee chair for the International Consultation on Bladder Tumors in 2004 Consensus. He has appeared before the FDA as an expert including the presentation that led to the historic approval of BCG for NMIBC. Dr. Jewett has published more than 400 peer-reviewed papers, mostly in Uro-oncology and in technology assessment and medical informatics. Dr. Jewett was a member of the inaugural Medical Advisory Board of the Bladder Cancer Advocacy Network (BCAN). He is an Honorary Member of the American Urological Association (AUA) and the European Association of Urology (EAU) and has been a visiting professor in more than 40 institutions and associations. In December 2020, Dr. Jewett was appointed to the Order of Canada based on his achievements listed above, among others.